KILR CD16 Effector Cells Advantages
- Eliminate Donor Variability - Primary effector cells from a single donor
- Fit for Long-Term QC Testing - High lot-to-lot reproducibility with frozen ready-to-use cells
- Measure Target Cell Death - Biologically relevant measure of ADCC and TCR
KILR Cytotoxicity Assays Have Broad Applications in:
Higher Signal:Background Ratios Deliver Better Accuracy and Linear Range
The KILR CD16 Effector Cells provide a significantly larger assay window in comparison to PBMCs. A killing- resistant HER2+ cell line, SKOV-3 was opsonized with trastuzumab and incubated with the effector cells for 3 hours. A 16-fold larger assay window was observed relative to PBMCs in this SKOV-3 cell model. These effector cells have much lower background with higher S:B ratios, resulting in better analysis of the antibody activity.
QC-Friendly, Ready-to-Use Effector Cells
KILR CD16 Effector Cells were thawed, then maintained in AssayComplete™ Cell Culture Kit 117 for the indicated number of days prior to use in ADCC assay with KILR Raji cells. These effector cells can be used in the ADCC assay after a resting period of 24 hours and show no reduction in their killing capacity even when
used on day 3 post-thaw. This easy-to-use format with robust performance allows for an easy implementation into QC as a lot release assay.
High Lot-to-Lot Reproducibility Ensures Long-Term Support for QC Testing
Four different production batches of KILR CD16 Effector Cells were tested for ADCC activity in a single experiment in the anti-human CD20 model. No significant variation in the killing capacity of the cells was observed. This excellent lot-to-lot reproducibility demonstrates the ability of these cells to deliver consistent and reproducible performance throughout the life of the drug from development to post-market.
|KILR CD16 Effector Cells, 1 Vial
|KILR CD16 Effector Cells, 5 Vials